Payment overview · 2025
General Payments
$91.00
5 reported records · 4 companies
Healthcare provider profile · identity verified
Michael Chris Goodhope, DO
Allopathic & Osteopathic Physicians|Family Medicine · RAPID CITY, SD · NPI 1861466872
Verified facts
What the public records show
CMS Open Payments records show Michael Chris Goodhope, DO received $91.00 in general payments during 2025 across 5 reported records.
Novartis Pharmaceuticals Corporation accounted for 44.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $40.06 | 44.0% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.37 | 20.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.13 | 18.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.44 | 17.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.00 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
81 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 794 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 555 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 357 | 89 |
| Omeprazole | Omeprazole | 356 | 81 |
| Losartan Potassium | Losartan Potassium | 347 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 270 | 69 |
| Lisinopril | Lisinopril | 249 | 63 |
| Simvastatin | Simvastatin | 245 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 49 |
| Valsartan | Valsartan | 203 | 48 |
| Gabapentin | Gabapentin | 196 | 51 |
| Potassium Chloride | Potassium Chloride | 181 | 42 |
| Allopurinol | Allopurinol | 176 | 41 |
| Metformin Hcl | Metformin Hcl | 167 | 43 |
| Trazodone Hcl | Trazodone Hcl | 167 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 43 |
| Finasteride | Finasteride | 158 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 33 |
| Furosemide | Furosemide | 146 | 30 |
| Tramadol Hcl | Tramadol Hcl | 130 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 24 |
| Jardiance | Empagliflozin | 115 | 32 |
| Eliquis | Apixaban | 114 | 27 |
| Sertraline Hcl | Sertraline Hcl | 108 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 27 |
| Meloxicam | Meloxicam | 92 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 35 |
| Metformin Hcl Er | Metformin Hcl | 90 | 20 |
| Donepezil Hcl | Donepezil Hcl | 89 | 19 |
| Glipizide Er | Glipizide | 85 | 21 |
| Mounjaro | Tirzepatide | 81 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 16 |
| Celecoxib | Celecoxib | 72 | 26 |
| Alendronate Sodium | Alendronate Sodium | 69 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 17 |
| Ozempic | Semaglutide | 64 | 13 |
| Glipizide | Glipizide | 63 | 17 |
| Ezetimibe | Ezetimibe | 61 | 16 |
| Atenolol | Atenolol | 60 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 14 |
| Warfarin Sodium | Warfarin Sodium | 56 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 12 |
| Chlorthalidone | Chlorthalidone | 50 | 14 |
| Clonidine Hcl | Clonidine Hcl | 49 | 12 |
| Montelukast Sodium | Montelukast Sodium | 49 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 13 |
| Famotidine | Famotidine | 48 | 12 |
| Spironolactone | Spironolactone | 48 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 13 |
| Lansoprazole | Lansoprazole | 46 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 45 | 11 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Terazosin Hcl | Terazosin Hcl | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Restasis | Cyclosporine | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Tri-Estarylla | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.00 · 5 records | Novartis Pharmaceuticals Corporation | LEQVIO, MOUNJARO, Veozah, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error